Midostaurin–Cladribine Therapy for Neonatal Aggressive Systemic Mastocytosis
Pediatric Blood & Cancer · 2026-06 · 73 (6)
DOI: 10.1002/1545-5017.70308 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 05.04.2026. Verfasst von Maria Frost und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Pediatrics, McGovern Medical School, UTHealth Houston, Houston, Texas, USA.
- Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh, Egypt.
- Division of Immunology, Allergy & Retrovirology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Maria Frost, Amr Elgehiny, Joud Hajjar, Hussein A Abbas
Zitieren
APA
Frost, M., Elgehiny, A., Dobbins, C., Saleh, A., Rosemore, C., Hajjar, J., Abbas, H. A., & McCall, D. (2026). Midostaurin–Cladribine Therapy for Neonatal Aggressive Systemic Mastocytosis. Pediatric Blood & Cancer, 73(6). https://doi.org/10.1002/1545-5017.70308
Vancouver
Frost M, Elgehiny A, Dobbins C, Saleh A, Rosemore C, Hajjar J, et al. Midostaurin–Cladribine Therapy for Neonatal Aggressive Systemic Mastocytosis. Pediatric Blood & Cancer. 2026;73(6). doi:10.1002/1545-5017.70308
BibTeX
@article{Frost2026,
author = {Frost, Maria and Elgehiny, Amr and Dobbins, Christopher and Saleh, Amr and Rosemore, Carly and Hajjar, Joud and Abbas, Hussein A and McCall, David},
title = {Midostaurin–Cladribine Therapy for Neonatal Aggressive Systemic Mastocytosis},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {6},
doi = {10.1002/1545-5017.70308}
}
EUVIMED